Ofatumumab (Arzerra) approved for recurrent or progressive chronic lymphocytic leukemia (CLL)
January 20, 2016 – The American Food and Drug Administration (FDA) just approved Ofatumumab (Arzerra) Injection for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL). Ofatumumab, also …